Gladstone Institutional Advisory LLC Sells 75,325 Shares of Humacyte, Inc. (NASDAQ:HUMA)

Posted by Defense World Staff on Apr 22nd, 2023

Gladstone Institutional Advisory LLC reduced its position in Humacyte, Inc. (NASDAQ:HUMA – Get Rating) by 86.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 12,098 shares of the company’s stock after selling 75,325 shares during the period. Gladstone Institutional Advisory LLC’s holdings in Humacyte were worth $26,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. United Asset Strategies Inc. lifted its holdings in shares of Humacyte by 83.6% in the 4th quarter. United Asset Strategies Inc. now owns 27,460 shares of the company’s stock worth $58,000 after purchasing an additional 12,500 shares in the last quarter. Private Advisor Group LLC lifted its holdings in shares of Humacyte by 20.4% in the 4th quarter. Private Advisor Group LLC now owns 29,500 shares of the company’s stock worth $62,000 after purchasing an additional 5,000 shares in the last quarter. Bank of New York Mellon Corp raised its position in Humacyte by 24.1% in the 3rd quarter. Bank of New York Mellon Corp now owns 69,776 shares of the company’s stock valued at $227,000 after buying an additional 13,536 shares during the last quarter. Marshall Wace LLP raised its position in Humacyte by 227.3% in the 3rd quarter. Marshall Wace LLP now owns 192,530 shares of the company’s stock valued at $628,000 after buying an additional 133,702 shares during the last quarter. Finally, Renaissance Technologies LLC raised its position in Humacyte by 1,773.9% in the 3rd quarter. Renaissance Technologies LLC now owns 208,000 shares of the company’s stock valued at $678,000 after buying an additional 196,900 shares during the last quarter. 13.05% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Benchmark reissued a “buy” rating and issued a $16.00 price target on shares of Humacyte in a research report on Monday, March 27th.

Humacyte Trading Down 0.6 %

Shares of Humacyte stock opened at $3.31 on Friday. Humacyte, Inc. has a 1 year low of $1.96 and a 1 year high of $7.83. The firm has a market cap of $342.02 million, a PE ratio of -25.46 and a beta of 1.21. The stock has a fifty day moving average price of $3.10 and a 200-day moving average price of $2.97. The company has a debt-to-equity ratio of 0.34, a current ratio of 7.88 and a quick ratio of 7.88.

Humacyte Company Profile

(Get Rating)

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs).